The indication of immunotherapy in renal cell carcinoma and other urological tumours

Supplementum 01/2019 Imunoterapie

MUDr. Alexandr Poprach, Ph.D.; MUDr. Radek Lakomý, Ph.D.

Klinika komplexní onkologické péče, Masarykův onkologický ústav a LF MU, Brno



The checkpoint inhibitors now belong to standard treatment options with metastatic renal cell carcinoma patients and significantly prolong overall survival of these patients. The results of the study phase I with combinations of targeted therapy and immunotherapy are also very promising, high response rates and prolonging of progression-free survivals/overall survivals were reached. But we have to wait for studies phase III results. Immunotherapy is also successful with urothelial cancers patients, especially with responders to this treatment. There is a high need to unify various methods of assessments PD-L1 expression which has both predictive and prognostic value. It was proven that combination of PD-L1 expressions and mutations loads of urothelial tumors improve estimation of response rate to the immunotherapy. The immunotherapy is very expensive, so it is important to have valid and reliable predictive factors. In this review, we summarize the up-to-date results of studies with immunotherapy, with renal cell carcinoma patients and urothelial cancers patients.



renal cell carcinoma, immunotherapy, overall survival, bladder cancer



The full article is only available to subscribers

Become a regular subscriber to our Oncological Review...